With the Ohio Medical Marijuana Program somewhat operational, below are a list of issues that needs correction. The biggest issue is the extreme cost of medical marijuana here in Ohio.
At last report, there were 83,857 recommendations with 78,376 registered patients and 55,617 Unique Purchasers who on average has made a little over 8 purchases at an average of $128.70. Given all that information, there are a number of serious concerns that are strangling the program’s success.
• Foremost is the excessive cost due to extraordinary high fees on the various business operations. This is directly reflected in the low number of purchases that have been made to date.
• The extremely slow process of the program becoming operational has caused patients to lose faith in the Ohio government's commitment to making this program a success. The administrative burden on the dispensaries has made long delays in making the program operational.
* Distance to the nearest dispensary is still an issue for some as a consequence of the slow process.
* Extra delays effectively increases the cost burden on the patients.
• The 90-day supply tracking program has been a mess. I commend Grant Miller for stepping in where he can and fixing individual patient’s records, but the system needs a major overall and to be simplified. OPN suggest a 90-day rolling average versus the current system that is prone to error and has everyone confused.
* Here is a small example, buying a one-day supply of three different Tier I products counts as 6 days. Hopefully, with proposed change to the rules on 3796:8-2-04 Part A and Part B of the supply rule will fix that issue.
* Buying a one-day unit of Tier I 45 days in a row will cause you to be locked out for the rest of the period.
• The depth of knowledge by the dispensary agents is uneven, some are knowledgeable, and some are not.
* Improve the educational level of dispensary agents and state employees as well. Perhaps attending some of the better conferences would be a benefit.
* There have been heavy-handed limits by the pharmacy board regarding educating the patients.
• The lack of reciprocity with other states, in particular with Michigan, Pennsylvania, and West Virginia is lacking and should be finalized by this time.
• Law enforcement needs training for interacting with card holding patients with marijuana or marijuana from an out of state source.
• Good product labeling is important for those with food sensitivities. Suggest similar format to foods or supplements to include active and inactive ingredients
• Bedridden patients have a very difficult time to obtain a Medical Marijuana Recommendation. OPN recommends a change in the law to the State Legislature regarding Doctor's in-person only visit. There are homebound patients that cannot physically get to a remote doctor for a recommendation. OPN recommends a temporary emergency rule change to cover this situation.
• The Common Sense Initiative (CSI) review has been blind to the administrative burden that has been implemented.
- Information from experts who specialize in the disease or condition
- Relevant medical or scientific evidence pertaining to the disease or condition
- Consideration of whether conventional medical therapies are insufficient to treat or alleviate the disease or condition
- Evidence supporting the use of medical marijuana to treat or alleviate the disease or condition, including journal articles, peer-reviewed studies, and other types of medical or scientific documentation
- Letters of support provided by physicians with knowledge of the disease or condition.
We addressed each requirement in exacting detail and share them with you below.
Information from experts who specialize in the disease or condition
Opioid Use Disorder/Opioid Addiction is the physical and psychological reliance on opioids found in prescription pain medications and illegal drugs like heroin and fentanyl derivatives. Addiction occurs when dependence interferes with daily life. Symptoms include uncontrollable cravings and inability to control opioid use. People may experience whole body craving, sweating, euphoria or general angst. Some common effects are constipation, nausea, and death due to overdose. See complete response at http://www.ohiopatientsnetwork.org/Data/Petition/Section1.pdf
Relevant medical or scientific evidence pertaining to the disease or condition
Included in the attached Section 2 PDF file is a variety of government reports detailing the relevant medical evidence of Opioid Use Disorder with reference links to the original reports. The documents address the scope and the science of addiction, including a commentary by Nora D. Volkow, M.D., Director, NIDA and more. The attachment also includes the most recent report from the National Center for Health Statistics listing Ohio as the second-highest in the nation for overdose. See complete response at http://www.ohiopatientsnetwork.org/Data/Petition/Section2.pdf
Consideration of whether conventional medical therapies are insufficient to treat or alleviate the disease or condition
Opioid Use Disorder is a complex condition that is not easily treated successfully. The patient usually has other associated mental and/or physical issues. According to NIDA the relapse rate for patients going through drug addiction treatment ranges from 40% to 60%. Twelve Step Facilitation programs have mixed success and are not well documented. The indisputable fact that we have such a tremendous number of overdose deaths indicates that conventional medical therapies are insufficient. See complete response at http://www.ohiopatientsnetwork.org/Data/Petition/Section3.pdf
Evidence supporting the use of medical marijuana to treat or alleviate the disease or condition, including journal articles, peer-reviewed studies, and other types of medical or scientific documentation.
In New York and Illinois, doctors can recommend medical marijuana for conditions where they prescribe an opioid. Pennsylvania & New Jersey permit patients to use medical marijuana for Opioid Use Disorder. These studies show a significant reduction in opioid prescriptions in states with marijuana states vs non-marijuana states. Included are newer studies done in 2019 that continue to show a significant reduction in opioid prescriptions in states with marijuana states vs non-marijuana states. Also included is a rebuttal of a study that undermined the numerous other studies' positive impact of Medical Marijuana on Opioid Use Disorder. You can also find reports that link medical marijuana to a reduction in the risk of opioid overdose and increased treatment retention. See complete response at http://www.ohiopatientsnetwork.org/Data/Petition/Section4.pdf
Letters of support provided by physicians with knowledge of the disease or condition.
Included in this section are PDF copies of physicians’ letters supporting adding Opioid Use Disorder/Opiate Addiction as a qualifying condition as well as a reference to 22 other Physicians. One is from Dr. Ethan Russo, a neurologist with drug development experiences and leadership positions in international research medical organizations. Dr. Blatman is an Ohio based pain practitioner and Dr. Sawyer is certified in Suboxone therapy. Dr. Kollman was co-author of the American Legion National 2017 Resolution that changed the policy towards medical marijuana in Veterans Administration Medical Facilities. Also included are three more Ohio Licensed physicians. All the physicians’ medical licenses have been independently verified and clear of any blemishes or negative reports. See Complete response at http://www.ohiopatientsnetwork.org/Data/Petition/Section5.pdf
Any rational evaluation of cannabis would dictate that should it be removed from the drug schedule. Now it appears that the Food and Drug Agency (FDA) is slowly starting to recognize the fallacy of cannabis (AKA Marijuana) being classified as a schedule 1 drug (definition of Schedule 1 is at the end of this article).
The FDA has now reopened the comment period on "International Drug Scheduling for Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis." Please take the time to take this additional time to submit comments to the FDA.
For more details and additional instructions see
To comment please use the link below, note all comments are due Sep 30 2019, at 11:59 PM ET
All submissions received must include the Docket No. FDA-2019-N-0767 for “International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis.”
The exact schedule 1 drug definition for marijuana per United States Law 21 U.S.C. ch. 13 § 801 signed by President Nixon in 1971 is listed below. Note Statements 1, 2, 3 are “LOGIC AND” legal statements.
1. There is a lack of accepted safety for use of the drug or other substance under medical supervision.
2. The drug or other substance has a high potential for abuse.
3. The drug or other substance has no currently accepted medical use in treatment in the United States.
OPN has submitted Opioid Use disorder (Opioid Addiction) with updated 2019 information for consideration to be added to the qualifying condition list for Ohio Medical Marijuana Control Program.
Thank you for your continued support.
Ohio Patient Network
The Medical Board of Ohio has been playing fast and loose with the 2018 Petition process as demonstrated in their last meeting regarding the Autism petition. As a result, OPN has submitted a Public Record request as follows.
.-.-.-.-.-.-.-.Public Record request -.-.-.-.-.
The State Medical Board of Ohio Meeting Minutes for June 12, 2019, states that on, “On May 8, the Board’s Medical Marijuana Expert Review Committee completed its review of the expert reports.”
Per Ohio’s Ohio Open Records I request a list of the members of the Medical Marijuana Expert Review Committee who reviewed the expert reports regarding the petitions to add qualifying conditions to the Ohio Medical Marijuana Control Program.
I also request all written reports and minutes compiled by the Medical Marijuana Expert Review Committee who reviewed the expert reports regarding the petitions to adding a qualifying condition to the Ohio Medical Marijuana Control Program.
Note OPN has a copy of the Experts Reports from an earlier Information request. The title of the PDF file is “Combined Subject Matter Expert Reports” with a creation date May 16th, 2019 that contain Drs Zaraa, Woyshville, and Parran reports on the Opioid Addiction/Opioid Use Disorder Anxiety Disorder, Insomnia, Depression, and Autism Spectrum Disorder.
Page 1 of 11